A Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Evaluate the Safety and Efficacy of DT2-SCT in Subjects With Type 2 Diabetes Mellitus
NCT ID: NCT06789302
Last Updated: 2025-08-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
120 participants
INTERVENTIONAL
2025-12-31
2028-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will be randomly assigned to receive either DT2-SCT or a placebo. They will undergo a single intravenous infusion after a liposuction procedure to collect adipose tissue, which will be processed to isolate stem cells for the therapy.
The study involves follow-up visits over six months to monitor safety, insulin resistance, blood sugar control, and any potential side effects.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes
NCT01576328
Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study
NCT01956305
Autologous Stem Cell and Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus
NCT01786707
A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes
NCT02653599
A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione
NCT00743002
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Design:
The trial involves 120 participants, randomized in a 1:1 ratio to receive either DT2-SCT or a placebo. The investigational product, DT2-SCT, consists of MSCs isolated from each participant's adipose tissue obtained via a tumescent liposuction procedure. The cells are processed, expanded, and prepared in a sterile, cryopreservation-free medium for a single intravenous infusion. The placebo consists of Plasma-Lyte A without MSCs.
Intervention and Monitoring:
Participants will undergo:
Screening and Enrollment: Eligibility will be determined based on inclusion and exclusion criteria, including a comprehensive review of medical history, laboratory tests, and diabetes status.
Liposuction Procedure: Approximately 50 mL of adipose tissue will be collected from the lower abdominal region under local anesthesia. The extracted tissue will be processed to isolate and expand MSCs.
Infusion Phase: Participants will receive either DT2-SCT (1 x 10\^6 cells/kg) or placebo in a 100 mL Plasma-Lyte solution via intravenous infusion over one hour. Safety will be monitored during and after the infusion.
Follow-Up Visits: Participants will be followed for six months, with evaluations at 7 days, 1 month, 3 months, and 6 months post-infusion. These visits include assessments of glycemic control, insulin resistance, adverse events, and overall health.
Objectives:
Primary Objective: To determine the safety and tolerability of a single intravenous dose of DT2-SCT in T2DM patients.
Secondary Objectives:
Assess changes in insulin resistance using the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR).
Evaluate changes in fasting blood glucose (FBG) and HbA1c levels compared to baseline.
Measure the reduction in insulin and oral glucose-lowering drug dosages.
Methodology:
The MSCs used in DT2-SCT are self-renewing, multipotent cells with documented capacity for differentiation into various cell types, including pancreatic β-cells. The mechanism of action includes immunomodulation, anti-inflammatory effects, and potential enhancement of β-cell regeneration. These properties suggest that DT2-SCT could address both insulin resistance and β-cell dysfunction in T2DM.
Statistical Considerations:
The sample size of 120 participants is designed to provide robust safety data and meaningful descriptive results for efficacy. An interim safety analysis will be conducted after the first 20 participants complete their 3-month follow-up.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A: DT2-SCT Infusion
Group A will be given DT2-SCT suspended on Plasma-Lyte A.
DT2-SCT intravenous infusion
DT2-SCT is an investigational therapy using autologous adipose-derived mesenchymal stem cells (MSCs) prepared from each participant's adipose tissue. MSCs are isolated from approximately 50 mL of adipose tissue obtained through a tumescent liposuction procedure. The cells are expanded, tested for contaminants, and suspended in a sterile, cryopreservation-free medium (Plasma-Lyte A) for administration.
The intervention involves a single intravenous infusion of DT2-SCT at a dosage of 1 x 10\^6 MSCs/kg body weight, delivered over a period of one hour. Participants will be closely monitored for at least two hours post-infusion to assess immediate safety and potential adverse effects.
Group B: Placebo Treatment
Group B will be given Plasma-Lite A only.
Placebo
Participants in the placebo group (Group B) will receive a single intravenous infusion of Plasma-Lyte A, a sterile, isotonic, non-pyrogenic crystalloid solution. The infusion will be administered in a volume of 100 mL over a period of one hour.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DT2-SCT intravenous infusion
DT2-SCT is an investigational therapy using autologous adipose-derived mesenchymal stem cells (MSCs) prepared from each participant's adipose tissue. MSCs are isolated from approximately 50 mL of adipose tissue obtained through a tumescent liposuction procedure. The cells are expanded, tested for contaminants, and suspended in a sterile, cryopreservation-free medium (Plasma-Lyte A) for administration.
The intervention involves a single intravenous infusion of DT2-SCT at a dosage of 1 x 10\^6 MSCs/kg body weight, delivered over a period of one hour. Participants will be closely monitored for at least two hours post-infusion to assess immediate safety and potential adverse effects.
Placebo
Participants in the placebo group (Group B) will receive a single intravenous infusion of Plasma-Lyte A, a sterile, isotonic, non-pyrogenic crystalloid solution. The infusion will be administered in a volume of 100 mL over a period of one hour.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Should have Type 2 diabetes mellitus
* With Insulin requirement of 0.7 IU/kg/d or 50 IU/d, whichever is lesser
* Glutamic acid decarboxylase (GAD) antibody status should be negative
* Body Mass Index (BMI) 19 - 30 kg/m2
* Fasting blood glucose (FBG) should be ≥ 7.0 mmol/L, and HbAc1 ≥ 7%
* Intravenous insulin tolerance tests (ITT) indicate a patient's insulin resistance
* Should be ambulatory and in good general health
* Willing and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions
* Willing to abstain from the use of protocol-restricted treatments from Screening through the End-of-Treatment
* No clinically significant abnormalities observed in medical history, physical exam vital signs, and laboratory assessments
* For females with reproductive potential: Should agree to use effective contraception for at least 1 month prior to screening and should agree to use such a method till end of the study period and negative pregnancy test
* For males with reproductive potential: should use condoms and other methods to ensure effective contraception with a partner
Exclusion Criteria
* Subjects with serum creatinine 1.5 mg/dl or higher
* Abnormal liver function test (defined as value of transaminases \> 3 times the upper limit of normal or serum bilirubin higher than normal for the reference value for the laboratory)
* History of myocardial infarction or unstable angina in previous 3 months
* History of malignancy or current malignancy other than non-melanomatous skin cancer
* Subjects with active infections
* Subject with serious medical conditions other than cardiovascular disease
* Subject with, or with a medical history of auto-immune diseases
* Subject with a medical history of mental disorder or epilepsy
* Subject abuse alcohol 10 times a week or smoke 25 cigarettes a day
* Subject who was diagnosed with cancer within 5 years before screening
* Subject who participated in another clinical trial within 6 months prior to the screening of this clinical trial
* Subject who was administered with immunosuppressants such as cyclosporin A or azathioprine within 6 weeks prior to the screening
* Serious life-threatening conditions
* Allergies to anesthesia
* Subject who is pregnant or nursing
* Subject is on chronic immunosuppressive transplant therapy
* Subjects who tested positive for HIV 1/2, HBV, HCV, HTLV I/II, WNV, and syphilis
* Flu symptoms
* Any past history of lipid disorders: lipedema, lipomatosis, or lipodystrophies
* Active cancer, chemotherapy, or other malignancies in the last 6 months prior to the screening
* Any past history of DVT or pulmonary embolism requiring anticoagulants or other medicines
* Requiring supplemental oxygen
* Major surgeries within 6 months prior to the screening
* Wounds/sepsis ongoing or within 3 months prior to the screening
* Any illness which in the Investigator's judgment, may interfere with the subject's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results
30 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Global Institute of Stem Cell Therapy and Research
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GIOSTAR-001-2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.